Jay Duker, MD

President and Chief Operating Officer

As President and Chief Operating Officer of EyePoint Pharmaceuticals, Jay S. Duker, M.D., leads all clinical development, regulatory affairs, and operations.

Dr. Duker has devoted more than 30 years to the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical, research, business, start-ups, and academic settings. He previously served as Chief Strategic Scientific Officer on a part-time basis since 2020 before joining EyePoint full-time in 2021. He was an independent member of the Board of Directors since 2016 and served as Chair of the Board’s Science Committee. Before joining EyePoint, Dr. Duker was Director of the New England Eye Center, one of the largest academic ophthalmology practices in the US, and Chair of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine. He also co-founded three businesses, including Hemera Biosciences, a gene therapy company that developed an anti-complement treatment for dry macular degeneration, which was acquired by Janssen in 2020.  

Dr. Duker is currently the Chair of the Board of Sesen Bio, a publicly traded clinical stage biopharmaceutical company, and Emeritus Editor of the International Journal of Retina and Vitreous. He has published over 350 journal articles focused on ophthalmology and is co-author of Yanoff and Duker’s Ophthalmology, a best-selling ophthalmic textbook, now in its sixth edition. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.